AN2 Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
AN2 Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q2 2024.
  • AN2 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$14.4M, a 8.66% increase year-over-year.
  • AN2 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$64.7M, a 19.1% decline year-over-year.
  • AN2 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$64.7M, a 58.1% decline from 2022.
  • AN2 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$41M, a 90.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$64.7M -$14.4M +$1.37M +8.66% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$66M -$16.6M -$1.29M -8.45% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-13
Q4 2023 -$64.7M -$16.9M -$5.06M -42.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$59.7M -$16.7M -$5.37M -47.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$54.3M -$15.8M -$5.68M -56.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$48.6M -$15.3M -$7.67M -100% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-13
Q4 2022 -$41M -$11.8M -$4.3M -57% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$36.7M -$11.3M -$4.4M -63.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$32.3M -$10.1M -$5.11M -102% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$27.2M -$7.66M -$5.61M -274% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$21.5M -$7.55M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$6.94M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$5.01M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$2.05M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.